Therapeutic targeting of the PI3K/Akt pathway and nuclear retention of FOXO1 could suppress the upregulation of MALAT1, re-sensitize the sensitivity of trastuzumab, and prevent breast cancer progression. This evidence concerns the gene PIK3CG and breast carcinoma.